PW Medtech Group Limited Announces Voluntary Termination of Sichuan Ruijian Medical’s Beijing Stock Exchange Listing Application

Key Highlights of the Announcement

• PW Medtech Group Limited (Stock Code: 1358) has announced the voluntary termination of the subsequent listing application of its subsidiary, Sichuan Ruijian Medical, on the Beijing Stock Exchange.
• This decision was made after a careful and prudent analysis of various factors, including business development direction and the current market environment.
• The termination is not immediate and is still subject to approval by the shareholders of Sichuan Ruijian Medical and the Beijing Stock Exchange.
• Investors are advised to exercise caution when dealing in the securities of PW Medtech Group Limited as this decision may be price-sensitive.

Details of the Announcement

The Board of PW Medtech Group Limited provided an update regarding the subsequent listing process of Sichuan Ruijian Medical. Previously, Sichuan Ruijian Medical had completed its NEEQS Quotation and submitted its application for subsequent listing on the Beijing Stock Exchange. However, on March 11, 2026, after in-depth communication with its sponsor and thorough research, it was decided that Sichuan Ruijian Medical would adjust its capital markets strategic plan and voluntarily terminate its application for the subsequent listing.

This is a significant strategic shift, given that the listing was expected to be a major transaction and a deemed disposal for PW Medtech Group Limited, potentially affecting the company’s capital structure and exposure in the capital markets.

Implications for Shareholders and Investors

• Potential Impact on Share Price: The voluntary termination of the listing could be perceived either positively or negatively by the market. On one hand, it might indicate caution in response to unfavorable market conditions, preserving shareholder value. On the other, it might signal a delay in unlocking capital market value for Sichuan Ruijian Medical, which could impact future growth prospects and valuation multiples.
• Approval Process: The termination is subject to further approvals by both the shareholders of Sichuan Ruijian Medical and the Beijing Stock Exchange. Any developments in this process could result in additional share price movements.
• Strategic Realignment: The decision reflects a reassessment of business priorities and market conditions, suggesting that management is focused on optimizing long-term value rather than pursuing listings amid uncertain environments.

Board Composition

As of the announcement date, the Board of PW Medtech Group Limited comprises:

• Executive Director: Ms. Yue’e Zhang (Chairman & Chief Executive Officer)
• Non-Executive Directors: Mr. Jiang Liwei and Mr. Lin Junshan
• Independent Non-Executive Directors: Mr. Wang Xiaogang, Mr. Chen Geng, and Ms. Wang Fengli

Investor Advisory

Shareholders and potential investors are strongly advised to monitor developments regarding the approval process, as these may have a direct impact on the share value of PW Medtech Group Limited. Decisions at the shareholder and regulatory level could alter the company’s strategic outlook and financial profile.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Investors should conduct their own research and consult professional advisers before making any investment decisions. PW Medtech Group Limited and its subsidiaries may be subject to further regulatory, shareholder, and market developments not covered herein.

View PW MEDTECH Historical chart here